840 related articles for article (PubMed ID: 15308713)
1. Codon optimization of the tat antigen of human immunodeficiency virus type 1 generates strong immune responses in mice following genetic immunization.
Ramakrishna L; Anand KK; Mohankumar KM; Ranga U
J Virol; 2004 Sep; 78(17):9174-89. PubMed ID: 15308713
[TBL] [Abstract][Full Text] [Related]
2. Generation and immunogenicity of novel HIV/AIDS vaccine candidates targeting HIV-1 Env/Gag-Pol-Nef antigens of clade C.
Gómez CE; Nájera JL; Jiménez V; Bieler K; Wild J; Kostic L; Heidari S; Chen M; Frachette MJ; Pantaleo G; Wolf H; Liljeström P; Wagner R; Esteban M
Vaccine; 2007 Mar; 25(11):1969-92. PubMed ID: 17224219
[TBL] [Abstract][Full Text] [Related]
3. Gene combination raises broad human immunodeficiency virus-specific cytotoxicity.
Calarota SA; Kjerrström A; Islam KB; Wahren B
Hum Gene Ther; 2001 Sep; 12(13):1623-37. PubMed ID: 11535166
[TBL] [Abstract][Full Text] [Related]
4. Human immunodeficiency virus type 1 Nef epitopes recognized in HLA-A2 transgenic mice in response to DNA and peptide immunization.
Sandberg JK; Leandersson AC; Devito C; Kohleisen B; Erfle V; Achour A; Levi M; Schwartz S; Kärre K; Wahren B; Hinkula J
Virology; 2000 Jul; 273(1):112-9. PubMed ID: 10891413
[TBL] [Abstract][Full Text] [Related]
5. The Tat protein broadens T cell responses directed to the HIV-1 antigens Gag and Env: implications for the design of new vaccination strategies against AIDS.
Gavioli R; Cellini S; Castaldello A; Voltan R; Gallerani E; Gagliardoni F; Fortini C; Cofano EB; Triulzi C; Cafaro A; Srivastava I; Barnett S; Caputo A; Ensoli B
Vaccine; 2008 Jan; 26(5):727-37. PubMed ID: 18096278
[TBL] [Abstract][Full Text] [Related]
6. Induction of neutralizing antibodies and Th1-polarized and CD4-independent CD8+ T-cell responses following delivery of human immunodeficiency virus type 1 Tat protein by recombinant adenylate cyclase of Bordetella pertussis.
Mascarell L; Fayolle C; Bauche C; Ladant D; Leclerc C
J Virol; 2005 Aug; 79(15):9872-84. PubMed ID: 16014948
[TBL] [Abstract][Full Text] [Related]
7. DNA immunization with HIV-1 tat mutated in the trans activation domain induces humoral and cellular immune responses against wild-type Tat.
Caselli E; Betti M; Grossi MP; Balboni PG; Rossi C; Boarini C; Cafaro A; Barbanti-Brodano G; Ensoli B; Caputo A
J Immunol; 1999 May; 162(9):5631-8. PubMed ID: 10228047
[TBL] [Abstract][Full Text] [Related]
8. DNA prime and protein boost immunization with innovative polymeric cationic core-shell nanoparticles elicits broad immune responses and strongly enhance cellular responses of HIV-1 tat DNA vaccination.
Castaldello A; Brocca-Cofano E; Voltan R; Triulzi C; Altavilla G; Laus M; Sparnacci K; Ballestri M; Tondelli L; Fortini C; Gavioli R; Ensoli B; Caputo A
Vaccine; 2006 Jul; 24(29-30):5655-69. PubMed ID: 16781023
[TBL] [Abstract][Full Text] [Related]
9. Cynomolgus macaques immunized with two HIV-1 Tat stabilized proteins raise strong and long-lasting immune responses with a pattern of Th1/Th2 response differing from that in mice.
Turbant S; Martinon F; Moine G; Le Grand R; Léonetti M
Vaccine; 2009 Aug; 27(39):5349-56. PubMed ID: 19607953
[TBL] [Abstract][Full Text] [Related]
10. Codon optimization and ubiquitin conjugation of human immunodeficiency virus-1 Tat lead to enhanced cell-mediated immune responses.
Ramakrishna L; Anand KK; Mahalingam M; Mohankumar KM; Ramani S; Siddappa NB; Ranga U
Vaccine; 2004 Jun; 22(20):2586-98. PubMed ID: 15193384
[TBL] [Abstract][Full Text] [Related]
11. Cross-clade protection induced by human immunodeficiency virus-1 DNA immunogens expressing consensus sequences of multiple genes and epitopes from subtypes A, B, C, and FGH.
Malm M; Rollman E; Ustav M; Hinkula J; Krohn K; Wahren B; Blazevic V
Viral Immunol; 2005; 18(4):678-88. PubMed ID: 16359234
[TBL] [Abstract][Full Text] [Related]
12. Induction of human immunodeficiency virus type-1-specific immunity with a novel gene transport unit (GTU)-MultiHIV DNA vaccine.
Blazevic V; Männik A; Malm M; Sikut R; Valtavaara M; Toots U; Ustav M; Krohn K
AIDS Res Hum Retroviruses; 2006 Jul; 22(7):667-77. PubMed ID: 16831091
[TBL] [Abstract][Full Text] [Related]
13. Designing and engineering of DNA-vaccine construction encoding multiple CTL-epitopes of major HIV-1 antigens.
Bazhan SI; Belavin PA; Seregin SV; Danilyuk NK; Babkina IN; Karpenko LI; Nekrasova NA; Lebedev LR; Ignatyev GM; Agafonov AP; Poryvaeva VA; Aborneva IV; Ilyichev AA
Vaccine; 2004 Apr; 22(13-14):1672-82. PubMed ID: 15068850
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity testing of a novel engineered HIV-1 envelope gp140 DNA vaccine construct.
Kumar S; Yan J; Muthumani K; Ramanathan MP; Yoon H; Pavlakis GN; Felber BK; Sidhu M; Boyer JD; Weiner DB
DNA Cell Biol; 2006 Jul; 25(7):383-92. PubMed ID: 16848679
[TBL] [Abstract][Full Text] [Related]
15. The grafting of universal T-helper epitopes enhances immunogenicity of HIV-1 Tat concurrently improving its safety profile.
Kashi VP; Jacob RA; Shamanna RA; Menon M; Balasiddaiah A; Varghese RK; Bachu M; Ranga U
PLoS One; 2014; 9(12):e114155. PubMed ID: 25531437
[TBL] [Abstract][Full Text] [Related]
16. Independent but not synergistic enhancement to the immunogenicity of DNA vaccine expressing HIV-1 gp120 glycoprotein by codon optimization and C3d fusion in a mouse model.
Liu F; Mboudjeka I; Shen S; Chou TH; Wang S; Ross TM; Lu S
Vaccine; 2004 Apr; 22(13-14):1764-72. PubMed ID: 15068860
[TBL] [Abstract][Full Text] [Related]
17. Multiple effects of codon usage optimization on expression and immunogenicity of DNA candidate vaccines encoding the human immunodeficiency virus type 1 Gag protein.
Deml L; Bojak A; Steck S; Graf M; Wild J; Schirmbeck R; Wolf H; Wagner R
J Virol; 2001 Nov; 75(22):10991-1001. PubMed ID: 11602739
[TBL] [Abstract][Full Text] [Related]
18. Influence of polypeptide size and intracellular sorting on the induction of epitope-specific CTL responses by DNA vaccines in a mouse model.
Wild J; Bojak A; Deml L; Wagner R
Vaccine; 2004 Apr; 22(13-14):1732-43. PubMed ID: 15068857
[TBL] [Abstract][Full Text] [Related]
19. Antibodies against a multiple-peptide conjugate comprising chemically modified human immunodeficiency virus type-1 functional Tat peptides inhibit infection.
Devadas K; Boykins RA; Hewlett IK; Wood OL; Clouse KA; Yamada KM; Dhawan S
Peptides; 2007 Mar; 28(3):496-504. PubMed ID: 17188401
[TBL] [Abstract][Full Text] [Related]
20. Cross-subtype T-cell immune responses induced by a human immunodeficiency virus type 1 group m consensus env immunogen.
Weaver EA; Lu Z; Camacho ZT; Moukdar F; Liao HX; Ma BJ; Muldoon M; Theiler J; Nabel GJ; Letvin NL; Korber BT; Hahn BH; Haynes BF; Gao F
J Virol; 2006 Jul; 80(14):6745-56. PubMed ID: 16809280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
